Repetitive Transcranial Magnetic Stimulation Improves Handwriting in Parkinson’s Disease

Table 1

Participant Characteristics.

P	Sex	Age	MoCA	UPDRS-III	H&Y	DH	More affected side	Disease duration (years)	Medication (daily dose—mg)
1	M	52	25	9	1.5	R	L	4	Levodopa/Carbidopa 100/25 QID; Entacapone 200 QID; Pramipexole 1 QID
2	M	73	28	18	1.5	R	R	10	Levodopa/Carbidopa CR 200/50 QID; Levodopa/Carbidopa/Entacapone 100/25/200 QID; Levodopa/Carbidopa 120/25 TID
3	M	77	27	11	1.5	R	L	4	Levodopa/Carbidopa 250 QD
4	M	77	24	13	1.5	R	R	4	Levodopa/Carbidopa CR 100/25 QID; Levodopa/Carbidopa 100/25 BID
5	M	71	29	7	1	R	R	8	Levodopa/Carbidopa CR 200-50 TID; Rasagiline 1 QD
6	M	77	29	9	1.5	R	L (more axial)	3	Levodopa/Carbidopa CR 100/25 QID
7	M	72	26	7	1.5	R	R (more axial)	5	Levodopa/Carbidopa 200/50 q5H; Pramipexole 1 TID
8	F	64	28	5	1.5	R	R (more axial)	6	Levodopa/Carbidopa CR 100/25 q5H; Pramipexole 1 TID; Rasagiline 0.5 QD
9	M	64	30	6	1.5	R	L	4	Levodopa/Carbidopa 100/25 QID; Pramipexole 0.5 QID
10	M	78	29	9	1.5	R	R	3	Levodopa/Carbidopa CR 200/50 QID

P: participant, Age: years, F: female, M: male, R: right; L: Left, MoCA: Montreal Cognitive Assessment, UPDRS-III: Unified Parkinson’s Disease Rating Scale-motor section, H&Y: Hoehn and Yahr’s stages, DH: dominant hand, CR: controlled release, QD: one/day, BID: two times/day, TID: three/day, QID: Four/day, q5H: Five/day.